CNS Leaders Tackle Pressing Issues in Alzheimer's, Autism and Schizophrenia Clinical Trials

NASHVILLE, Tenn.--(BUSINESS WIRE)--As researchers worldwide await the results from several important clinical trials of new medicines for Alzheimer’s disease, the International Society for CNS Clinical Trials and Methodology (ISCTM) will host a panel of experts discussing the role of genotyping in the development of new Alzheimer’s therapies.

“With the recent disappointments in phase II and III Alzheimer's disease clinical trials, stratified medicine approaches have gained increasing interest. Our session gathers the leaders in this work, using ApoE4 carriage as an example of an approach to targeted clinical trials designs for new treatments in Alzheimer's disease”

“With the recent disappointments in phase II and III Alzheimer's disease clinical trials, stratified medicine approaches have gained increasing interest. Our session gathers the leaders in this work, using ApoE4 carriage as an example of an approach to targeted clinical trials designs for new treatments in Alzheimer's disease,” according to Lon S. Schneider, MD, Professor of Psychiatry, Neurology, and Gerontology, University of Southern California, Keck School of Medicine. Dr. Schneider is a co-chair of the half-day session entitled Stratified Medicine and Targeted Clinical Trials for Alzheimer's Disease Drug Development in Light of Recent Phase III Trial Results: Example ApoE Genotype.

Other plenary sessions include Clinical Trials in Autism Spectrum Disorders: Methods, Measurements, Designs and Outcomes which will be an in-depth review of best practices for the design of drug development programs targeting these complex developmental disabilities. Eight concurrent workshops provide attendees the opportunity for detailed work in targeted areas, and the evening Poster session offers further interaction among attendees. (Full Autumn Conference Program)

Every gathering of the ISCTM includes an international set of representatives from academia, the pharmaceutical industry, regulatory and governmental agencies, with session agendas developed to allow time for robust and interdisciplinary discussions about research processes. The ISCTM Autumn Meeting, October 1-3, 2012, Marina del Rey, CA, will include 3 days of scientific sessions focused on some of the most challenging issues in developing new treatments for mental illness.

“ISCTM is a critical forum for stakeholders in CNS clinical research. We are tremendously enthusiastic about our Autumn meeting agenda, and look forward to healthy and provocative discussions that will help move the field forward,” stated Richard Keefe, PhD, President of ISCTM.

Early bird Registration discount is available through August 15.